Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company, announced its anticipation to file a Registration Statement on Form S-4 with the SEC before the end of October 2024.
This filing relates to the previously announced proposed Business Combination with Denali Capital Acquisition Corp. The transaction is associated with a pre-transaction equity value of $2.5 billion for Semnur.
The business combination is expected to occur by the end of the fourth quarter of 2024 or the first quarter of 2025, aiming to unlock significant value for Scilex's shareholders through its majority stake in Semnur.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.